Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma

PharmacoEconomics

Volumn 20, Issue 13, 2002, Pages 909-918

  Sheth, K ^a   Borker, R ^b   Emmett, A ^b   Rickard, K ^b   Dorinsky, P ^b  

^a Clarian Arnett Health   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEVICE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HUMAN; INFLAMMATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THRUSH; TREATMENT OUTCOME;

EID: 0036033843     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220130-00004     Document Type: Article

References (24)

1. National Institutes of Health. Practical Guide for the Diagnosis and Management of Asthma. Washington (DC): US Department of Health and Human Services, National Institutes of Health; 1997. Publication No.: 97-4053
2. Centers for Disease Control and Prevention. Forecasted statespecific estimates of self-reported prevalence in the United States, 1998. Morb Mortal Wkly Rep 1998; 47: 1022-5
3. Centers for Disease Control and Prevention. National Center for Health Statistics Fact Sheet [Online]. Available from URL: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma/asthma.htm [Accessed 2002 Jul 24]
4. Weiss K, Sullivan S. The health economics of asthma and rhinitis: Assessing the economic impact. J Allergy Clin Immunol 2001; 107: 3-8
5. Lundback B, Jenkins C, Price M, et al. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μg twice daily and budesonide 800 μg twice daily in the treatment of adults and adolescents with asthma., Respir Med 2000; 94: 724-32
6. Hoskins G, McCowan C, Neville R, et al. Risk factors and costs associated with an asthma attack. Thorax 2000; 55: 19-24
7. Brinke A, Ouwerkerk M, Zwmderman A, et al. Psychopathology in patients with severe asthma is associated with increased health care utilization. Am J Respir Crit Care Med 2001; 163: 1093-6
8. Reiss T, Chervinsky P, Dockhom R, et al. Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma. Arch Intern Med 1998; 158: 1213-20
9. Calhoun W, Nelson H, Nathan R, et al. Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short acting β2 agonists alone. Am J Respir Crit Care Med 2001; 164: 759-63
10. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Task Force on the Cost Effectiveness, Quality of Care and Financing of Asthma Care. Bethesda (MD): National Institutes of Health, 1996. Publication no. 55-807
11. Current Competitive Price Positions, Copyright © 2001. Facts and Comparisons 2002. Available from URL: http://www.factsandcomparisons.com [Accessed 2002 Sep 25]
12. Cardinale V, editor. 2001 Drug Topics Red Book. Montvale (NJ): Medical Economics Co, 2001
13. Stanford R, McLaughlin T, Okamoto L. The cost of asthma in the emergency department and hospital. Am J Respir Crit Care Med 1999; 160: 211-5
14. Crane M. Charge what you will...Reimbursements are shrinking. Med Econ 2000; 75: 128-38
15. Campbell F, Hollis S. What is mean by intention to treat analysis: Survey of published randomized controlled trials. BMJ 1999; 319: 670-4
16. Rutten-van Molken M, Van Doorslaer E, Jansen M, et al. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 975-82
17. Menendez R, Stanford RH, Edwards L, et al. Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma. Pharmacoeconomics 2001; 19 (8): 865-74
18. Volmer T, Kielhom A, Weber HH, et al. Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma. Pharmacoeconomics 1999 Nov; 16 (5 Pt 2): 525-31
19. Lord J, Asante M. Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis. Health Econ 1999; 8: 323-33
20. Kielhorn A, Schulenburg J. The Health Economic Handbook. 2nd Ed. Chester: Adis International Ltd, 2000
21. Drummond M, Brien B, Stoddart G, et al. Methods for Economic Evaluation of Health Care Programs. 2nd Ed. Oxford: Oxford University Press, 1997
22. Pearlman D, White M, Lieberman A. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistant asthma. Ann Allergy Asthma Immunol 2002; 88: 227-35
23. Stempel D, O'Donnell J, Myer J. Inhaled corticosteroids plus salmeterol or montelukast: Effects on resource utilisation and costs. J Allergy Clin Immunol 2002; 109: 433-9
24. O'Conner R, O'Donnell J, Pinto L, et al. Two year retrospective economic evaluation of three dual controller therapies used in the treatment of asthma. Chest 2002; 121: 1028-35